EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120

Debashree Chatterjee, Ling Niu, Halima Medjahed, Shilei Ding, Mehdi Benlarbi, Étienne Bélanger, Jérémie Prévost, Hung-Ching Chen, William D Tolbert, Amos B Smith, Marzena Pazgier iD, Andrés Finzi iD

Journal of Virology · 2025

DOI: 10.1128/jvi.02267-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Debashree Chatterjee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du CHUM, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: HIV Envelope Protein gp120, HIV-1, HIV Envelope Protein gp41, Anti-HIV Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Canadian Government | Canadian Institutes of Health Research (CIHR), HHS | National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One characteristic of the HIV-1 CRF01_AE strain is that it contains a bulkier histidine residue at position 375 (H375) in its envelope glycoproteins (Env). This residue is part of the Phe43 cavity, where residue 43 of CD4 engages with gp120. It has been shown that H375 contributes to resistance against small molecule inhibitors targeting gp120. Residue 375 co-evolved with a few residues of the gp120 inner domain layers, and together they modulate the susceptibility of Env to small molecule gp120 inhibitors. Since residue 629 within the HR2 region of gp41 has also been proposed to have co-evolved with residue 375, we explored its role in the susceptibility of HIV-1 Env to two classes of small molecule gp120 inhibitors: the conformational blocker temsavir and the CD4-mimetic (CD4mc) BNM-III-170. Reversion of CRF01_AE isoleucine to a major clade methionine at position 629 had a significant but opposite impact on the susceptibility of the virus to temsavir and BNM-III-170. Mechanistically, this is associated with the capacity of residue 629 to modulate Env stability, as attested by its impact on cold inactivation. Overall, our results show how a single residue of HR2 contributes to the overall Env trimer stability and its susceptibility to gp120-targeted small molecule inhibitors. IMPORTANCE CRF01_AE envelope glycoproteins (Env) have a well-conserved histidine at position 375. This residue is key in modulating the susceptibility of HIV-1 to small molecule Env inhibitors. Here, we report that a residue of the gp41 HR2 region affects Env trimer stability and its susceptibility to gp120-directed small molecule inhibitors. This work adds to our understanding of HIV-1 Env resistance to small molecule inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV Envelope Protein gp120HIV-1HIV Envelope Protein gp41Anti-HIV AgentsHumansDrug Resistance, ViralHIV InfectionsCD4 Antigens

Stichwörter der Autor:innen

CD4mcCRF01_AEEnvHIVgp120gp41temsavir

Substanzen

HIV Envelope Protein gp120HIV Envelope Protein gp41gp120 protein, Human immunodeficiency virus 1Anti-HIV AgentsCD4 Antigens

Autor:innen und Institutionen

  • Centre de Recherche du CHUM, Montreal, Québec, Canada.
  • Infectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Québec, Canada.
  • Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Marzena Pazgier, Andrés Finzi

Förderung

  • NIAID NIH HHS
  • Canadian Government | Canadian Institutes of Health Research (CIHR)
  • HHS | National Institutes of Health (NIH)
  • Canada Foundation for Innovation (CFI)

Zitieren

APA

Chatterjee, D., Niu, L., Medjahed, H., Ding, S., Benlarbi, M., Bélanger, É., Prévost, J., Chen, H. C., Tolbert, W. D., Smith, A. B., Pazgier, M., & Finzi, A. (2025). A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120. Journal of Virology. https://doi.org/10.1128/jvi.02267-24

Vancouver

Chatterjee D, Niu L, Medjahed H, Ding S, Benlarbi M, Bélanger É, et al. A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120. Journal of Virology. 2025. doi:10.1128/jvi.02267-24

BibTeX
@article{Chatterjee2025,
  author = {Chatterjee, Debashree and Niu, Ling and Medjahed, Halima and Ding, Shilei and Benlarbi, Mehdi and Bélanger, Étienne and Prévost, Jérémie and Chen, Hung-Ching and Tolbert, William D and Smith, Amos B and Pazgier, Marzena and Finzi, Andrés},
  title = {A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.02267-24}
}
Kostenlos starten →